Organ Preservation, for Rectal Cancer: General Overview of the Latest Data from Phase III Randomized Trials

Overview

Journal Acta Oncol

Date 2025 Jan 28

PMID 39871514

Authors

Syrine Ben Dhia

Damien Chauviere

Diana Mitrea

Renaud Schiappa

Tanguy Pace Loscos

Emmanuel Chamorey

David Baron

Affiliations

Soon will be listed here.

Abstract

Introduction: Organ preservation (OP) strategies are gaining interest in improving the quality of life in the management of rectal cancer, particularly for tumors located in the distal or middle rectum. The optimal OP protocol is still not standardized and relies on randomized trials. This review summarizes past and ongoing studies on OP protocols for adenocarcinoma of the distal and middle rectum.

Method: We searched for articles and abstracts on randomized clinical trials investigating OP approaches for rectal cancer, including data presented at the LUCARRE Congress held in Nice on November 25, 2023, covering ongoing and recently published trials on rectal preservation.

Results: Our review's findings are presented in four tables: the first evaluates key trials with overall survival (OS) as the primary endpoint; the second provides an overview of past Phase III trials; the third reviews Phase II/III trials that specifically focus on local excisions (LE); and finally, the fourth summarizes ongoing trials. Each table is accompanied by detailed comments elucidating the significance and implications of the presented data, alongside a review of current guidelines.

Interpretation: We highlight the growing interest in OP strategies for rectal cancer management to enhance patients' quality of life. Despite the lack of international consensus on the optimal OP protocol, past and ongoing randomized trials provide valuable findings into the evolving management strategies of rectal cancer treatment. The presented data supports the role of randomized phase III trials to provide evidence for a change in clinical practice.

References

Garant A, Kavan P, Martin A, Azoulay L, Vendrely V, Lavoie C . Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial. Radiother Oncol. 2020; 155:237-245. DOI: 10.1016/j.radonc.2020.11.008. View

Garcia-Aguilar J, Renfro L, Chow O, Shi Q, Carrero X, Lynn P . Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015; 16(15):1537-1546. PMC: 4984260. DOI: 10.1016/S1470-2045(15)00215-6. View

Bennett H, Rao C, Batten L, Hasler E, Jarrom D, Prettyjohns M . Low energy contact X-ray brachytherapy for treatment of rectal cancer: a health technology appraisal by Health Technology Wales. Colorectal Dis. 2024; 26(5):1053-1058. DOI: 10.1111/codi.16935. View

Heald R, Ryall R . Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986; 1(8496):1479-82. DOI: 10.1016/s0140-6736(86)91510-2. View

Francois E, De Bari B, Ronchin P, Nouhaud E, Martel-Lafay I, Artru P . Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial. Eur J Cancer. 2022; 180:62-70. DOI: 10.1016/j.ejca.2022.11.020. View

Weiser M . AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018; 25(6):1454-1455. DOI: 10.1245/s10434-018-6462-1. View

Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech J, Valverde A . Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020; 5(5):465-474. DOI: 10.1016/S2468-1253(19)30410-8. View

Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer G, Fietkau R . Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2021; 8(1):e215445. PMC: 8603234. DOI: 10.1001/jamaoncol.2021.5445. View

Serra-Aracil X, Pericay C, Badia-Closa J, Golda T, Biondo S, Hernandez P . Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). Ann Oncol. 2022; 34(1):78-90. DOI: 10.1016/j.annonc.2022.09.160. View

10.

Bosset J, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A . Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. J Clin Oncol. 2005; 23(24):5620-7. DOI: 10.1200/JCO.2005.02.113. View

11.

Schrag D, Shi Q, Weiser M, Gollub M, Saltz L, Musher B . Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023; 389(4):322-334. PMC: 10775881. DOI: 10.1056/NEJMoa2303269. View

12.

Grotenhuis B, Beets G . Watch-and-Wait is an Option in Rectal Cancer Patients: From Controversy to Common Clinical Practice. Clin Oncol (R Coll Radiol). 2022; 35(2):124-129. DOI: 10.1016/j.clon.2022.11.011. View

13.

Kennecke H, OCallaghan C, Loree J, Moloo H, Auer R, Jonker D . Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results. J Clin Oncol. 2022; 41(2):233-242. PMC: 9839227. DOI: 10.1200/JCO.22.00184. View

14.

Garcia-Aguilar J, Patil S, Gollub M, Kim J, Yuval J, Thompson H . Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022; 40(23):2546-2556. PMC: 9362876. DOI: 10.1200/JCO.22.00032. View

15.

Fokas E, Appelt A, Glynne-Jones R, Beets G, Perez R, Garcia-Aguilar J . International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat Rev Clin Oncol. 2021; 18(12):805-816. DOI: 10.1038/s41571-021-00538-5. View

16.

Ali F, Keshinro A, Weiser M . Advances in the treatment of locally advanced rectal cancer. Ann Gastroenterol Surg. 2021; 5(1):32-38. PMC: 7832958. DOI: 10.1002/ags3.12389. View

17.

Jin J, Tang Y, Hu C, Jiang L, Jiang J, Li N . Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022; 40(15):1681-1692. PMC: 9113208. DOI: 10.1200/JCO.21.01667. View

18.

Bach S, Gilbert A, Brock K, Korsgen S, Geh I, Hill J . Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2020; 6(2):92-105. PMC: 7802515. DOI: 10.1016/S2468-1253(20)30333-2. View

19.

El Sissy C, Kirilovsky A, Van den Eynde M, Musina A, Anitei M, Romero A . A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. Clin Cancer Res. 2020; 26(19):5198-5207. DOI: 10.1158/1078-0432.CCR-20-0337. View

20.

Gerard J, Barbet N, Schiappa R, Magne N, Martel I, Mineur L . Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023; 8(4):356-367. DOI: 10.1016/S2468-1253(22)00392-2. View